Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Ephedrine Sulfate Injection USP, 50 mg/mL single-dose vials, the company announced through an exchange filing.
Ephedrine Sulfate Injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).
Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States.
The group now has 368 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Bombay HC Issues Notice To State Government Over Lack Of Toilets Oon Mumbai-Pune Expressway
Mumbai Cyber Fraud: Father-Daughter Duo Loses ₹11.93 Lakh In Fake Medical Insurance Scam; Case Registered
Mumbai Crime: Police Book 45 For Vandalising Commercial Building In Kandivali, Damages Estimated At ₹1.5 Crore
Madhya Pradesh News: CBI Court Sentences Former Sub-Post Master To 5 Years Of Imprisonment For Fraudulent Withdrawals
